How should Platinib be taken and how much dose should be taken each time?

Pralsetinib (Pralsetinib) is an oral receptor tyrosine kinase RET (Rearranged during Transfection) inhibitor, mainly used to treat RET gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients, as well as patients with advanced or metastatic RET-mutant medullary thyroid carcinoma (MTC) and RET fusion-positive thyroid cancer who require systemic treatment. In order to ensure the effectiveness and safety of the drug, patients should take Platinib strictly in accordance with their doctor's recommendations and instructions.

Regarding the dosage and usage of Platinib, the recommended dose is 400 mg once a day, taken orally on an empty stomach. This means that patients should avoid eating for at least 2 hours before taking platinib and for at least 1 hour after taking it. Dosing this way helps ensure that the medication is fully absorbed and utilized.

In order to ensure the therapeutic effect and reduce the occurrence of adverse reactions, patients should continue to take platinib until the disease progresses or unacceptable toxicity occurs. If you forget to take platinib after a dose, you should take it as soon as possible that day. However, on the next day, patients should resume their regular once-daily dosing schedule and continue with the next dose as originally planned. It should be noted that if vomiting occurs after taking the drug, the patient does not need to take an additional dose and will continue to take the next dose as planned.

In addition, patients need to be careful to avoid concurrent use with strongCYP3A inducers while taking platinib. If this cannot be avoided, the starting dose should be increased to twice the current dose starting on day 7 of coadministration of platinib with a strong CYP3A inducer. After discontinuing the induction agent for at least 14 days, patients should resume it at their previous dose.